Master PRECISE v2: Better Prostate Cancer Monitoring

Master PRECISE v2: Better Prostate Cancer Monitoring

Prostate cancer monitoring MRI is an essential tool for managing patients on active surveillance. Specifically, the Prostate Cancer Radiologic Estimation of Change in Sequential Evaluation (PRECISE) criteria offer a structured way to report serial scans. The recently released PRECISE version 2 provides updated guidelines to improve communication between clinicians and radiologists. Therefore, doctors can now more effectively distinguish between stable disease and progression.

Advancing Prostate Cancer Monitoring MRI Protocols

Standardizing the evaluation of longitudinal scans is crucial for patient safety. PRECISE version 2 addresses this by introducing refined subcategories for stable findings. For example, radiologists now distinguish between visible (3-V) and non-visible (3-NonV) stable disease. Furthermore, the protocol mandates a comparison with both the baseline and the most recent previous scan. Consequently, this multi-point comparison helps identify subtle interval changes that a single comparison might miss.

Enhanced Quality Standards and Reporting

Maintaining high image quality is a primary focus of the updated version. Specifically, the guidelines recommend using the Prostate Imaging Quality (PI-QUAL) score to ensure scans are sufficient for surveillance. Additionally, the update clarifies PRECISE 5 to represent progression to stage T3a or higher. This clarity allows urologists to make faster decisions regarding when to switch from surveillance to active treatment. As a result, the management of low-risk prostate cancer becomes more precise and risk-adapted.

Frequently Asked Questions

Q1: What is the main change in PRECISE Version 2 regarding stable disease?

Version 2 sub-divides stable MRI findings into two categories: visible disease (3-V) and non-visible disease (3-NonV), providing more granular detail for clinicians.

Q2: Why must radiologists compare the current scan to both baseline and previous scans?

Comparing scans to both points allows for a better understanding of slow, long-term growth versus sudden, rapid changes in lesion size or appearance.

Q3: How does PRECISE Version 2 handle image quality?

The update emphasizes the use of standardized tools like the PI-QUAL score to confirm that the image quality is adequate for making clinical decisions.

References

1. Ogata A et al. PRECISE Version 2: Essential Tips for Prostate Cancer Monitoring Using MRI. Radiographics. 2026 May undefined. doi: 10.1148/rg.250126. PMID: 42060486.
2. Englman C, et al. PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer. European Urology. 2024 Sep;86(3):240-255. doi: 10.1016/j.eururo.2024.03.023.